Fisher & Paykel Healthcare (ASX: FPH) announced that its F&P ViteraTM, a new mask for obstructive sleep apnea (OSA), is now available for sale in US.
The company also upgraded the earnings and revenue guidance for the FY ended 31 March 2020. FPH expects the operating revenue to be ~$1.19 billion and net profit after tax to be in range of ~255-265 million.
The upgraded guidance also incorporates a further weakening of NZ Dollar and refinement of expected R&D tax credit.
At AEST (01:12 PM), the stock was trading at $17.080, up by 7.018 per cent from the previous close.